Online citations, reference lists, and bibliographies.
← Back to Search

Electrophysiological Effects Of Disopyramide In Patients With Bundle Branch Block.

J. Desai, M. Scheinman, R. Peters, J. O'Young
Published 1979 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Electrophysiological studies were performed in 22 patients with intraventricular conduction delay before and after intravenous infusion of disopyramide (Norpace), 2 mg/kg. Mean control maximal sinus node recovery time (1039 +/- 187 msec), atrioventricular nodal conduction time (113 +/- 28 msec), and atrioventricular nodal effective refractory periods (349 +/- 67 msec) did not change significantly after administration of disopyramide (1073 +/- 284 msec, 112 +/- 31 msec, and 342 +/- 42 msec, respectively). Mean spontaneous cycle length (756 +/- 146 msec) decreased significantly 5 minutes after disopyramide (717 +/- 124 msec) (p less than 0.05), but not after 30 minutes (734 +/- 142 msec). A small but statistically significant (p less than 0.05) increase occurred after disopyramide in the mean atrial effective refractory period (259 +/- 51 to 280 +/- 53 msec), ventricular effective refractory period (253 +/- 23 to 275 +/- 33 msec), as well as the relative refractory period of the ventricular specialized conduction system (six patients) 433 +/- 78 to 479 +/- 62 msec). Although mean control infranodal conduction time (67 +/- 35 msec) increased 5 minutes after disopyramide (79 +/- 41 msec) (p less than 0.001) (18%), no spontaneous episodes of second-degree or third-degree atrioventricular block were observed. In six patients with premature ventricular depolarizations (greater than or equal to 1/min), the arrhythmia was totally abolished in four, markedly reduced in one, and remained unchanged in one. Disopyramide resulted in significant prolongation of infranodal conduction time as well as in atrial and ventricular refractoriness, but nevertheless appears to be safe in patients with bundle branch block.
This paper references
Pharmacology of a new antiarrhythmic agent, -y-diisopropyl-amino-a-phenyl-a-(2-pyridyl)- butyramide (SC-7031)
Cm Mokler (1962)
Clinical evaluation of a new anti-arrhythmic agent, SC-7031.
M. Katz (1963)
10.1161/01.CIR.39.3.287
Study of Atrioventricular Conduction in Man Using Electrode Catheter Recordings of His Bundle Activity
A. D'Amato (1969)
The effects of procaine amide on atrioventricular and intraventricular conduction in man. (abstr)
Km Rosen (1969)
The effects of procaine amide on atrioventricular and intraventricular conduction in man. (abstr) Circulation
K M Rosen (1969)
The effects of procaine amide on atrioventricular and intraventricular conduction in man
KM Rosen (1969)
10.1161/01.RES.27.3.345
Patterns of Atrioventricular Conduction in the Human Heart
A. Wit (1970)
10.1016/0002-8703(72)90069-5
Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate.
P. Mathur (1972)
10.1016/0002-8703(73)90280-9
Electrophysiological evaluation of disopyramide in man.
M. Josephson (1973)
10.1002/JPS.2600621203
Effects of disopyramide on electrophysiological and mechanical properties of the heart.
B. K. Yeh (1973)
Electrophysiologic properties of diphenylhydantoin in man
Ar Caracta (1973)
10.1161/01.CIR.50.1.114
Effect of Procaine Amide, Quinidine, and Ajmaline in the Wolff‐Parkinson‐White Syndrome
H. Wellens (1974)
10.1002/cpt1974162330
Disopyramide phosphate: Clinical efficacy of a new oral antiarrhythmie drug
L. Vismara (1974)
10.1161/01.CIR.50.6.1150
Demonstration of Re‐entry within the His‐Purkinje System in Man
M. Akhtar (1974)
10.1161/01.CIR.49.5.894
The Electrophysiologic Effects of Lidocaine in Patients with Intraventricular Conduction Defects
F. Kunkel (1974)
10.1016/0002-9149(74)90248-3
Electrophysiologic properties of procainamide in man.
M. Josephson (1974)
10.1161/01.CIR.49.3.522
Electrophysiologic Effects of Procaine Amide in Patients with Intraventricular Conduction Delay
M. Scheinman (1974)
10.1016/0002-8703(74)90283-X
The electrophysiology of propranolol in man.
S. Seides (1974)
10.1016/0002-8703(74)90391-3
The electrophysiological effects of intramuscular guinidine on the atrioventricular conducting system in man.
M. Josephson (1974)
Interventricular reentry in patients with pre - existing right / left bundle branch block
M Akhtar (1974)
Amsterdam EA: Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug
LA Vismara (1974)
10.1136/hrt.37.8.861
Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.
R. A. Spurrell (1975)
10.1016/0002-9149(75)90014-4
Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate.
B. Befeler (1975)
The electrophysiology of Norpace (Part II).
B. Befeler (1975)
The electrophysiology of Norpace (Part I).
L. Dreifus (1975)
The electrophysiology of Norpace (Part III).
A. Caracta (1975)
Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrio-224 in Wolff-Parkinson-White syndrome
Raj Spurrell (1975)
ventricular pathway in Wolff-Parkinson-White syndrome
(1975)
The electrophysiology of Norpace (PartIII)
AR Caracta (1975)
A double-blind study on the effect of oral disopyramide in the prophylaxis of arrhythmias following acute myocardial infarction
Emm Besterman (1975)
Angiology
(1975)
The electrophysiology of Norpace (PartII)
B Befeler (1975)
A double - blind study on the effect of oral disopyramide in the prophylaxis of arrhythmias following acute myocardial infarction
Besterman EMM (1975)
10.1016/S0140-6736(76)90148-3
ORAL DISOPYRAMIDE IN PROPHYLAXIS OF ARRHYTHMIAS FOLLOWING MYOCARDIAL INFARCTION
G. Jennings (1976)
Acute termination of cardiac arrhythmias with intravenous disopyramide.
H. Mizgala (1976)
10.1016/0002-9149(76)90687-1
Efficacy of oral disopyramide phosphate for long-term treatment of ventricular arrhythmias☆
A. Nichols (1976)
10.1136/BMJ.1.6058.446
Disopyramide in ventricular fibrillation.
D. P. Atukorale (1976)
10.1016/0002-9149(76)90706-2
Disopyramide efficacy and kinetics in ventricular tachyarrhythmia
R. Rangno (1976)
Disopyramide in the treatment and prevention of arrhythmias following myocardial infarction.
N. Zainal (1976)
A study of the acute electrophysiological and cardiovascular action of disopyramide in man.
P. Marrott (1976)
10.1111/J.0954-6820.1976.TB08221.X
Disopyramide in ventricular tachycardia.
J. Hulting (2009)
10.1016/S0002-8703(76)80403-6
Disopyramide: serum level and arrhythmia conversion.
A. Niarchos (1976)
10.1161/01.CIR.54.3.436
Analysis of Secondary Pauses Following Termination of Rapid Atrial Pacing in Man
D. Benditt (1976)
10.1016/S0002-8703(76)80054-3
Cardiac effects of disopyramide.
P. Danilo (1976)
The antiarrhythmic effects of intravenous disopyramide. (abstr)
Da Deano (1976)
The antiarrhythmic effects of intravenous disopyramide
DA Deano (1976)
10.1016/S0002-9149(77)80218-X
Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia.
L. Vismara (1977)
10.1378/CHEST.71.5.597
The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
D. A. Deano (1977)
10.1016/0002-9149(76)90708-6
Effect of procainamide on reentry within the His-Purkinje system in man.
C. Reddy (1977)
10.1016/S0140-6736(77)90829-7
ORAL DISOPYRAMIDE FOR THE PREVENTION OF ARRHYTHMIAS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ADMITTED TO OPEN WARDS
N. Zainal (1977)
10.1136/hrt.39.3.309
Clinical and electrophysiological effects of intravenous quinidine in man.
D. S. Hirschfeld (1977)
10.1136/bmj.1.6065.903-e
Effect of intravenous disopyramide on premature beats.
T. Jones (1977)
10.1016/S0140-6736(77)92305-4
ARRHYTHMIA PREVENTION IN EARLY MYOCARDIAL INFARCTION
J. Ward (1977)
10.1136/hrt.39.6.657
Dual effect of disopyramide on atrial and atrioventricular conduction and refractory periods.
J. Birkhead (1977)
10.1378/CHEST.71.3.426
Resistant ventricular tachycardias and recurrent cardiac arrests. 96 episodes.
R. H. Harner (1977)
10.5694/j.1326-5377.1977.tb130600.x
ORAL DISOPYRAMIDE IN THE MANAGEMENT OF CARDIAC ARRHYTHMIAS
J. Sloman (1977)
Interventricular reentry in patients with pre-existing right/left bundle branch block. (abstr)
M Akhtar (1977)
High dose disopyramide phosphate: an effective treatment for refractory ventricular tachycardia. (abstr) Circulation
J J Gallagher (1977)
Disopyramide in ventricular fibrillation. (letter)
T D De Lanerolle (1977)
Disopyramide in ventricular fibrillation. (letter)
Td De Lanerolle (1977)
High dose disopyramide phosphate: an effective treatment for refractory ventricular tachycardia. (abstr)
Jj Gallagher (1977)
TD: Disopyramide in ventricular fibrillation
de Lanerolle (1977)
High dose disopyramide phosphate: an effective treatment for refractory ventricular tachycardia
JJ Gallagher (1977)
Interventricular reentry in patients with pre-existing right/left bundle branch block. (abstr) Circulation 56
M Akhtar (1977)
10.1161/01.CIR.59.2.226
Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction.
A. Labarre (1979)
Pharmacology of a new antiarrhythmic agent ,ydiisopropylaminoaphenyla( 2pyridyl )butyramide ( SC7031 )
CM Mokler
Searle New Drug Application 17-447 FDA
Caracta AR: The electrophysiology of Norpace (PartIII)



This paper is referenced by
10.2165/00003495-198122050-00002
New Antiarrhythmic Drugs: Their Place in Therapy
D. Keefe (1981)
10.1111/j.1540-8159.1998.tb00017.x
Pharmacological Stress Testing of the His‐Purkinje System in Patients with Bifascicular Block
Anders Enclund (1998)
10.1016/0002-9149(94)90465-0
Atrioventricular block progression in patients with bifascicular block assessed by repeated electrocardiography and a bradycardia-detecting pacemaker.
L. Bergfeldt (1994)
10.1016/0167-5273(94)90006-X
Mechanism of the suppression of repetitive atrial firing by isoproterenol--comparison with disopyramide.
A. Shimizu (1994)
10.1016/0002-8703(91)90178-K
Use of disopyramide by arrhythmia specialists after Cardiac Arrhythmia Suppression Trial: patient selection and initial outcome.
E. Prystowsky (1991)
10.1007/978-3-0348-7133-4_6
The oral antiarrhythmic drugs.
P. Podrid (1990)
10.1007/978-3-642-73666-7_9
Clinical Use of Class Ia Antiarrhythmic Drugs
T. Campbell (1989)
10.1016/0002-9149(89)90899-0
Effect of disopyramide on initiation of atrial fibrillation and relation to effective refractory period.
M. Ito (1989)
10.1016/0002-9149(88)90747-3
Chronic ventricular arrhythmias: which drug for which patient?
R. Dibianco (1988)
10.11281/SHINZO1969.20.11_1341
症例 完全房室ブロックを生じたW-P-W症候群と特発性肥大型心筋症の合併症例
成憲 貴田岡 (1988)
10.2165/00003495-198734020-00001
Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.
R. Brogden (1987)
10.1111/j.1540-8159.1986.tb06617.x
Atrial Pacing via Unilateral Persistent Left Superior Vena Cava
E. Robbens (1986)
Disopyramide induced second andthird degree atrioventricular block inpatients withbifascicular block
L. Bergfeldt (1985)
10.1136/hrt.53.3.328
Disopyramide induced second and third degree atrioventricular block in patients with bifascicular block. An acute stress test to predict atrioventricular block progression.
L. Bergfeldt (1985)
10.1016/0033-0620(84)90009-4
Bundle branch block.
J. McA'Nulty (1984)
10.1038/clpt.1984.84
Intravenous disopyramide: Safety and efficacy of a new dosage regimen
C. P. Reddy (1984)
10.5105/JSE.4.319
Electrophysiological effects of disopyramide phosphate in human specialized conduction system
Jiro Yoshino (1984)
10.1007/978-3-642-68872-0_12
Bradykarde Rhythmusst??rungen
H. Neuss (1983)
10.1016/S0002-9149(83)80129-5
Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation.
B. Lerman (1983)
10.1161/01.CIR.67.1.38
The Direct Electrophysiologic Effects of Disopyramide Phosphate in the Transplanted Human Heart
R. Bexton (1983)
10.1007/978-1-4613-3855-0_8
Clinical use of antiarrhythmic drugs
L. Gettes (1983)
10.1161/01.CIR.66.2.454
Effects of Oral Disopyramide Phosphate on Induction and Sustenance of Atrioventricular Reentrant Tachycardia Incorporating Retrograde Accessory Pathway Conduction
H. Kou (1982)
10.7326/0003-4819-96-3-337
Drugs Five Years Later: Disopyramide
F. Morady (1982)
10.1161/01.CIR.66.6.1211
Electrophysiologic Effects of Disopyramide in Patients with Atrioventricular Nodal Dysfunction
P. Wilkinson (1982)
10.1111/j.1540-8159.1982.tb02311.x
Electrophysiological Effects of Intravenous Disopyramide Phosphate on the Wolff‐Parkinson‐White Syndrome
T. Tajima (1982)
10.1016/0002-8703(82)90346-5
Flecainide-induced QT prolongation and ventricular tachycardia.
H. Lui (1982)
10.1253/JCJ.46.693
Electrophysiological effects of disopyramide phosphate in patients with sinus node dysfunction.
Y. Tsuchioka (1982)
10.1001/JAMA.1981.03320190060033
Chronic bundle-branch block. Clinical significance and management.
J. McA'Nulty (1981)
10.5105/JSE.1.77
Electrophysiogic effects of disopyramide phosphate in human hearts
K. Kaseno (1981)
10.1007/978-94-009-8239-0_8
Approach to the Patient with Bundle Branch Block
D. Ross (1981)
10.1007/978-94-009-8287-1_13
Effect of Antiarrhythmic Drugs on Intraven­tricular Conduction
P. Alboni (1981)
10.1378/CHEST.79.5.545
Cardiovascular collapse associated with disopyramide therapy.
J. M. Desai (1981)
See more
Semantic Scholar Logo Some data provided by SemanticScholar